Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 SAX treatments characteristics

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

  N = 148 (%)
First line
 Sutent 148 100
Sutent schedule
 Modified 27 18
 Standard 121 82
Axitinib dose
 Standard 113 76.4
 Titration 35 23.6
Therapy after axitinib 73 49